-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Upgrades Arcus Biosciences to Buy, Raises Price Target to $28

Benzinga·01/13/2026 17:25:04
Listen to the news
Goldman Sachs analyst Richard Law upgrades Arcus Biosciences (NYSE:RCUS) from Neutral to Buy and raises the price target from $16 to $28.